Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, discusses outcomes of primary refractory disease and early relapse in patients with relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) treated with salvage therapy and autologous stem cell transplant (ASCT). Patients who relapsed within 1 year of diagnosis were highly likely to receive more than one line of salvage regimen before stem cell transplant, and they were less likely to be successfully bridged after 1 line of salvage therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.